Background
Methods
Epidemiological methods/contact tracing
Drug susceptibility testing
Whole genome sequencing
Clinical data
Results
Microbiological data and genome-based molecular surveillance of TB
Drug | Phenotypical susceptibility testing | Associated mutations |
---|---|---|
Rifampicin/Rifabutin | Resistant | rpoB gene: mutation S531L |
Isoniazid | Resistant | katG gene: mutation S315T |
Isoniazid/Ethionamide | Resistant | inhA promotor: mutation T-8C |
Ethambutol | Resistant | embB gene: mutation M306I |
Pyrazinamide | Resistant | pncA gene: mutation T47A |
Levofloxacin | Resistant (0,5 mg/l) | gyrA gene: wild type gyrB gene: mutation E540N |
Susceptible (1 mg/l) | ||
Moxifloxacin | Resistant (0,25 mg/l) | |
Susceptible (1 mg/l) | ||
Aminoglycosides | Susceptible | rrs gene: wild type eis gene: wild type |
Cycloserine | Susceptible | |
Para-aminosalicylic acid (PAS) | Susceptible | |
Linezolid | Susceptible | |
Bedaquiline | Susceptible | |
Clofazimine | Susceptible | |
Delamanid | Susceptible |
Clinical and radiological findings
Patient | Sex | Age at diagnosis | Country of birth | Diagnosis | Disease mani-festation | AFB microscopy | TB culture from respiratory sample | IGRA |
---|---|---|---|---|---|---|---|---|
Patient 1 | F | 20 y | Sudan | 05/2018 | Pulmonary | +++ | + | + |
Patient 2 | M | 6 mo | Germany | 05/2018 | Pulmonary | +++ | + | + |
Patient 3 | M | 28 y | Sudan | 08/2018 | Pulmonary | (+) | + | + |
Patient 4 | F | 3 y + 10 mo | Sudan | 07/2018 | Pulmonary | – | – | + |
Patient 5 | F | 19 y | Sudan | 06/2018 | Pulmonary | (+) | + | + |
Patient 6 | M | 6 mo | Germany | 06/2018 | Pulmonary | ++ | + | + |
Patient 7 (index) | M | 50 y | Georgia | 06/2017 | Pulmonary | +++ | + | + |